Trial NCT04452318
Publication O'Brien M, JAMA, 2022
Primary outcome on the report: The proportion of participants who had a positive RT-qPCR result at baseline or during the 28-day efficacy assessment period and who developed signs and symptoms of COVID-19 within 14 days of the positive RT-qPCR result.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.